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R1/2 antagonist, astressin. The following experiments were performed: Effects of (i) serial blood 
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ABSTRACT 
Corticotropin releasing factor (CRF) is a major mediator of central and peripheral responses to 
environmental stressors, and antagonism of its receptors (CRF-R1, -R2) is an active area of 
pharmacotherapeutic research for stress-related disorders. Stress responses include CRF 
activation of the hypothalamus-pituitary-adrenal axis and behavioural inhibition. Valid in vivo 
models for the study of these neuro-endocrine and -behavioural CRF pathways and their central-
peripheral antagonism are important. The aims of this study in C57BL/6 mice were to describe 
the acute effects of intracerebroventricular (ICV) CRF using plasma ACTH-CORT titres and 
locomotor activity as readouts, and to study the impact on these readouts of central versus 
peripheral pretreatment with the CRF-R1/2 antagonist, astressin. The following experiments were 
performed: Effects of (i) serial blood sampling (SBS) per se, (ii) physical confinement + SBS, (iii) 
ICV saline infusion + SBS, on plasma titres of ACTH-CORT. (iv) Effects of ICV or IP CRF infusion 
on plasma ACTH-CORT. (v) Effects of ICV CRF on plasma CRF. (vi) Effects of ICV or IP 
astressin on ICV or IP CRF-stimulated plasma CORT. (vii) Effects of ICV or IP astressin on ICV 
CRF-induced locomotor inactivity. Main findings were: (i)-(ii) Serial blood sampling per se and 
physical confinement + SBS led to similar, mild increases in plasma ACTH-CORT. (iii) ICV saline 
infusion led to a marked increase in plasma ACTH, possibly due to assay crossreactivity with 
“washed out” pituitary peptides, and a mild increase in plasma CORT. (iv) ICV CRF (0.001-1 µg) 
induced no further increase in plasma ACTH versus vehicle, and induced dose-dependent 
increased plasma CORT. 1 µg ICV CRF also reduced locomotor activity. (v) ICV CRF induced 
dose-dependent increased plasma CRF. (vi) ICV astressin failed to block ICV CRF-induced 
increased plasma CORT, whereas IP astressin did do so. (vii) ICV CRF-induced locomotor 
inactivity was blocked by ICV astressin, but not by IP astressin. Therefore, ICV CRF induced a 
dose-dependent increase in plasma CORT via a peripheral pathway and a reduction in 
locomotion via a central pathway, indicated by the double dissociation in the ability of astressin to 
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antagonize these effects relative to its route of administration, IP or ICV, respectively. The 
preparation described here could be readily used to provide initial indications on the central and 
peripheral activity of CRF-R antagonists, including pharmacokinetics following peripheral 
administration. 
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ABSTRACT 
Corticotropin releasing factor (CRF) is a major mediator of central and peripheral responses to 
environmental stressors, and antagonism of its receptors (CRF-R1, -R2) is an active area of 
pharmacotherapeutic research for stress-related disorders. Stress responses include CRF 
activation of the hypothalamus-pituitary-adrenal axis and behavioural inhibition. Valid in vivo 
models for the study of these neuro-endocrine and -behavioural CRF pathways and their central-
peripheral antagonism are important. The aims of this study in C57BL/6 mice were to describe 
the acute effects of intracerebroventricular (ICV) CRF using plasma ACTH-CORT titres and 
locomotor activity as readouts, and to study the impact on these readouts of central versus 
peripheral pretreatment with the CRF-R1/2 antagonist, astressin. The following experiments were 
performed: Effects of (i) serial blood sampling (SBS) per se, (ii) physical confinement + SBS, (iii) 
ICV saline infusion + SBS, on plasma titres of ACTH-CORT. (iv) Effects of ICV or IP CRF infusion 
on plasma ACTH-CORT. (v) Effects of ICV CRF on plasma CRF. (vi) Effects of ICV or IP 
astressin on ICV or IP CRF-stimulated plasma CORT. (vii) Effects of ICV or IP astressin on ICV 
CRF-induced locomotor inactivity. Main findings were: (i)-(ii) Serial blood sampling per se and 
physical confinement + SBS led to similar, mild increases in plasma ACTH-CORT. (iii) ICV saline 
infusion led to a marked increase in plasma ACTH, possibly due to assay crossreactivity with 
“washed out” pituitary peptides, and a mild increase in plasma CORT. (iv) ICV CRF (0.001-1 µg) 
induced no further increase in plasma ACTH versus vehicle, and induced dose-dependent 
increased plasma CORT. 1 µg ICV CRF also reduced locomotor activity. (v) ICV CRF induced 
dose-dependent increased plasma CRF. (vi) ICV astressin failed to block ICV CRF-induced 
increased plasma CORT, whereas IP astressin did do so. (vii) ICV CRF-induced locomotor 
inactivity was blocked by ICV astressin, but not by IP astressin. Therefore, ICV CRF induced a 
dose-dependent increase in plasma CORT via a peripheral pathway and a reduction in 
locomotion via a central pathway, indicated by the double dissociation in the ability of astressin to 
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1. Introduction 
Corticotropin releasing factor (CRF) is a neurohormone and neurotransmitter and a major 
mediator of physiological and behavioural responses to environmental stressors (Vale et al., 
1981). An extensive immunohistochemical mapping study in rat (Swanson et al., 1983) 
describes: CRF-stained cells in the paraventricular nucleus of the hypothalamus (PVH) and 
CRF-stained fibres in the neurohaemal zone of the median eminence; a series of CRF-stained 
cell groups in the basal forebrain (e.g. central amygdala) and brain stem, inter-connected by 
CRF-stained fibres in medial forebrain bundle; and scattered CRF-stained cells throughout most 
areas of the cerebral cortex. An extensive in situ hybridization mapping study of mRNAs for 
CRF receptor type 1 (CRF-R1) and type 2 (CRF-R2) has been conducted in rat and mouse 
brains and pituitary glands (Van Pett et al., 2000): in both species, CRF-R1 exhibits high 
expression in the pituitary and a wide distribution throughout the CNS with regions of high 
expression including prefrontal cortex, amygdala, bed nucleus of stria terminalis (BNST), 
septum, basal ganglia, brain stem (e.g. periaqueductal gray, pre- and post-cerebellar regions) 
and cerebellum. CRF-R2 is not expressed in the pituitary, and CNS regions of high expression 
are more limited and include septum, BNST and brain stem dorsal raphé nucleus. The CRF 
synthesised by the parvocellular cells of the PVH and released into the median eminence 
reaches the pituitary and, in the CRF-R1-expressing corticotrope cells of the anterior pituitary, 
stimulates the synthesis and secretion of ACTH, which in turn stimulates corticosteroid secretion 
from the cortex of the adrenal gland. 
In vivo study of regulation of ACTH-corticosteroid release and behavioural processes by CRF is 
important with respect to the psychoneuroendocrinology of the stress response and 
development of antagonists of CRF hyperactivity as a potential treatment for stress-related 
disorders. Examples of important questions are does/how does forebrain CRF released as a 
5 
 
neurotransmitter regulate PVH CRF neuroendocrine activity, and how do CRF-receptor 
antagonists regulate ACTH-corticosteroid levels and behaviour. Some of the first major in vivo 
studies of CRF effects involved intra-venous (IV) or intracerebroventricular (ICV) infusion of 
CRF and measurement of its effects on circulating ACTH and corticosteroid levels, in rat (Rivier 
et al. 1982) and rhesus macaque (Rock et al., 1984). In both species there was a dose-related 
increase in ACTH and corticosteroid blood levels. In rats, ICV CRF has been demonstrated to 
induce activation, as immediate-early gene protein FOS induction, throughout the CNS with the 
activation pattern closely mimicking the distribution of CRF-R1 receptors (Bittencourt and 
Sawchenko, 2000). Behavioural studies in rat demonstrated that ICV CRF leads to, for example, 
increased locomotor activity in a familiar cage, decreased activity in a novel open field, and 
increased anxiety on an elevated plus maze (Koob et al., 1993; Sutton et al., 1982). These 
effects were antagonized by peptidergic CRF-R1/R2 antagonists (Spina et al., 2000). In mice, 
ICV CRF has been demonstrated to induce activation, as increased local cerebral glucose 
utilization, in hypothalamic, thalamic, cerebellar and hippocampal regions (Warnock et al., 
2009). It also increased plasma corticosterone (CORT) levels (Warnock et al., 2009). 
Behavioural effects of ICV CRF in mice include decreased activity in a novel open field and 
increased time spent in the centre of the open field related to a delay in leaving the centre after 
being placed there at the onset of the test (Swiergiel et al., 2008). A number of transgenic 
mouse strains that chronically over-express CRF have been developed and phenotyped in 
terms of HPA and behavioural status. Constitutive-transgenic mice over-expressing CRF, 
including in those regions/cells expressing endogenous CRF, exhibit increased basal plasma 
ACTH and CORT levels (Stenzel-Poore et al., 1992), hypo-activity in a novel cage and on an 
elevated plus maze, and reduced percent time on the open arms, probably reflecting 
increased anxiety, on the elevated plus maze (Stenzel-Poore et al., 1994). Conditional-
transgenic mice in which CRF over-expression is restricted to and pertains throughout the CNS, 
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exhibit no phenotype in terms of basal plasma ACTH and CORT levels and increased ACTH 
and CORT responses to a restraint stressor (Lu et al., 2008).  
Alongside the utilisation of transgenic mice to study the effects of chronic central CRF over-
expression and the neuropharmacology of CRF-R antagonism and agonism thereon, it is also 
important to have well-described mouse models based on acute increases in exogenous central 
CRF administration. These models can provide a first level of readout on the central and 
peripheral activity of CRF-R antagonists, including pharmacokinetic properties following 
peripheral administration, prior to study in transgenic models. In the present study, ICV CRF 
neuroendocrine challenge was conducted in C57BL/6 mice. The first aim was to describe the 
dose-related effects of ICV CRF on plasma ACTH and CORT levels and locomotor activity. The 
second and related aim was to utilize the same preparation to investigate the effects of prior 
treatment with a CRF-R1/R2 antagonist on ICV CRF-induced changes in plasma ACTH-CORT 
levels and locomotor activity. The antagonist used was astressin [cyclo(30-33) [D-Phe12, Nle21-
38, Glu30, Lys33]-hCRF(12-41)] (Spina et al., 2000). In rat, astressin is a potent antagonist of IV-
CRF stimulation of ACTH when pre-administered IV and also when administered ICV at a high 
dose (Rivier et al., 1996; Turnbull et al., 1999). ICV Astressin also reverses the anxiogenic 
effect of ICV CRF on the elevated plus maze in rats (Spina et al., 2000). In the present study the 
effects of pre-treatment with ICV versus IP astressin on ICV CRF stimulation of ACTH and 
CORT blood levels were studied, as were the effects of ICV versus IP astressin on ICV CRF 
induced changes in locomotor activity. Firstly, the demonstration that ICV CRF stimulates 
changes in plasma ACTH and CORT levels and locomotor activity levels would allow for the 
study of astressin effects on these readouts. Secondly, any effects of astressin, given ICV or IP, 
would provide insights into the pathway via which ICV CRF regulates these endocrine and 
behavioural readouts. Thirdly, therefore, the validity of the readouts in terms of providing initial 
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indications on the central or peripheral activity of putative CRF-R antagonists, could be 
assessed. 
2. Materials and Methods 
2.1. Animals and maintenance 
C57BL/6N male mice (Janvier, Le Genest St. Isle, France) were maintained in pairs in Macrolon 
type II cages (27 x 21 x 15 cm; containing sawdust, a sleeping chamber, tissue paper and a 
wood stick), with water and pellet food available ad libitium. The colony room was on a reversed 
light-dark cycle (dark phase 0800-2000 h) with temperature at 22°C and humidity at 50%. Mice 
were handled for 5 min on each of 3 days prior to the experiment. All procedures were 
conducted under a permit for animal experimentation issued by the Veterinary Office, Basel, 
Switzerland in accordance with the Animal Protection Act (1978) Switzerland. All efforts were 
made to minimise the number of mice used and any suffering of those mice that were used. 
2.2. Drugs 
CRF (Sigma, St. Louis, MO, USA) was dissolved in physiological saline at the appropriate 
concentrations for ICV infusion or IP injection. CRF dissolved in saline and administered ICV 
has been demonstrated to induce activation throughout the CNS in mouse (local cerebral 
glucose utilization (Warnock et al., 2009)) and rat (immediate-early gene protein FOS induction 
(Bittencourt and Sawchenko, 2000)). Astressin (Bachem AG, Bubendorf, CH) was dissolved in 
double-distilled water at appropriate concentrations for ICV infusion or IP injection. Solutions 
were prepared immediately before use each day. 
2.3. Surgery and brain cannulation 
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Mice (n = 130) were brain cannulated at age 10 weeks and experiments were conducted 2 
weeks later. Mice were pre-treated with analgesic (Temgesic, 0.05 mg/ml/kg), anaesthetized 
with ketamine (100 mg/kg) + xylazine (10 mg/kg) and operated on a warming pad. The head 
was fixed in a stereotaxic frame and mice were prepared with 26-gauge bilateral cannulas 
(Plastics One) aimed above the lateral ventricles (-0.3 mm posterior to bregma, 1.0 mm lateral 
from the midline, -1.4 mm ventral from skull surface) (Franklin and Paxinos, 2008). Cannulas 
were attached to the skull using adhesive gel and secured with stainless steel screws and 
dental acrylic; dummy cannulas were inserted and maintained during the recovery period. 
2.4. Blood sampling 
Blood sampling involved placing the mouse in a plastic restrainer with the tail protruding through 
a hole in the end of the tube, making a diagonal incision on the lateral tail surface about 15 mm 
from the distal tip, and massaging 60 µl of blood into an EDTA-coated capillary blood tube. 
Serial blood samples were collected at intervals from the same incision site. Mice were returned 
to the home cage in the intervals between successive blood samplings. Trunk blood sampling 
was conducted via decapitation and collection of the blood (300-500 µl) into an EDTA-coated 
tube (Microvette 500, Sarstedt). All samples were placed immediately on ice and centrifuged at 
4°C followed by removal and storage of plasma in Lo-bind cryotubes at -80°C until hormone 
determination.  
2.5. Physical confinement stressor 
Mice were placed singly in transparent plastic tubes (L = 10 cm x  = 4 cm; Indulab, Gams, 
CH), which were novel and in which they could move and turn, for 5 min. Immediately following 
removal from the tube, mice were restrained briefly for tail vein blood sampling (time = min 0). 
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Mice were then returned to the home cage and colony room, and retrieved at min 20, 60 and 
120 for serial blood sampling. 
2.6. ICV CRF infusion 
Cannulated mice were transferred in their home cage to an adjacent dimly-lit procedures room. 
The mouse was placed in a type II cage filled with sawdust and without lid; mice had been 
placed in the same cage for 5 min on each of 3 days prior to the experiment. Two 33-gauge 
internal cannulas extending 1.4 mm below the guide cannulas and connected to a double 
microinfusion pump were inserted. The mouse was able to move in the cage, with the delivery 
tube held by the experimenter, whilst CRF was infused in a total volume of 1.5 µl per ventricle 
during 5 min. The cannulas were removed 1 min after the end of infusion to allow for diffusion. 
After completion of each experiment, methylene blue dye solution was infused into each 
cannula, using the same method and volume used for CRF delivery, the brains were removed 
and frozen and sections were cut on a cryostat to assess cannula placement. Those animals 
with dye in the lateral ventricles and third ventricle were included in the analysis. 
2.7. Astressin pre-treatment 
For the study of the effects of ICV astressin pretreatment, cannulated mice were connected with 
the microinfusion apparatus as described above. Astressin was infused in a total volume of 2 µl 
per ventricle during 5 min. The cannulas were removed 1 min after the end of infusion and the 
mice returned to the home cage for 15 min, and were then infused ICV with CRF. For the study 
of IP effects, astressin was injected at a volume of 5 ml/kg, the mice returned to the home cage 
for 15 min, and were then infused ICV with CRF. 
After completion of each experiment, methylene blue dye solution was infused into each 
cannula and histology was performed to confirm ICV cannula placement, as described above. 
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2.8. Locomotor activity in mice 
Locomotor activity was measured using an in-house apparatus comprising a type-IV cage rack 
that was covered at the back with aluminium and with aluminium shutters that allowed access to 
each cage from the front. Each isolated compartment was illuminated with a dim white house 
light (10 lux) and contained a type IV cage (60 x 38 x 20 cm) without lid and with fresh sawdust. 
A small video camera was located in the ceiling of each compartment and the image was sent 
to a frame grabber and analysis software. Percent second-to-second change in pixel activation 
was calculated and provided an arbitrary measure of two-dimensional activity per second. Total 
activity per 5-minute block was calculated per mouse. Mice were placed in the compartments for 
2 daily 60 min habituation sessions during the 2-3 days prior to the experiment. 
2.9. Experiments 
All experiments were performed within the daily time period of 1200-1800 h i.e. during the 
second-half of the dark/active period. 
i. Effect of serial blood sampling on plasma ACTH and CORT. Naive mice (n = 8) were 
blood sampled at min 0, 20, 60 and 120. 
ii. Effect of physical confinement on plasma ACTH and CORT. Naive mice (n = 8) were 
exposed to 5-min confinement in a novel plastic tube followed by blood sampling at min 0, 20, 
60 and 120. In 8 additional mice, removal from the home cage was followed immediately by 
blood sampling for measurement of basal ACTH-CORT titres. 
iii. Effect of ICV saline infusion on plasma ACTH and CORT. Naive cannulated mice (n = 6) 
were infused ICV with saline, followed by blood sampling at min 20, 60 and 120. In 6 additional 
cannulated mice, removal from the home cage was followed immediately by blood sampling for 
measurement of basal ACTH-CORT titres. 
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iv. Effect of ICV CRF on plasma ACTH and CORT. Cannulated mice (n = 6 per group) were 
ICV infused with CRF at a total (i.e. both ventricles combined) dose of 0 µg, 0.001 µg (ca. 0.2 
pmol), 0.01 µg (ca. 2 pmol), 0.1 µg (ca. 20 pmol), or 1 µg (ca. 0.2 nmol). The cannulas were 
removed (time = min 0) and the mouse returned to its home cage and colony room, and 
retrieved at min 20, 60 and 120 for serial blood sampling.  
v. Effect of ICV CRF on plasma CRF. Cannulated mice (n = 3-4 per group) were ICV 
infused with CRF at a dose of 0 µg, 0.1 µg or 1 µg, and 10 min later trunk blood was collected 
via decapitation. 
vi. Effect of ICV or IP astressin X ICV CRF on plasma CORT. Cannulated mice (n = 6 per 
group) were pre-treated with astressin, either ICV infusion (0 or 2 µg (ca. 0.6 nmol)) or IP 
injection (0 or 35 µg/kg/5 ml (10 nmol)), and after 15 min were ICV infused with CRF (0 or 0.1 
µg). The cannulas were removed (time = min 0) and the mouse returned to its home cage and 
colony room, and retrieved at min 20, 60 and 120 for serial blood sampling. To test effects of 
ICV astressin, groups were icvVEH+icvVEH, icvAST+icvVEH, icvVEH+icvCRF and 
icvAST+icvCRF. To test effects of IP astressin, groups were ipVEH, ipVEH+icvCRF and 
ipAST+icvCRF. 
vii. Effect of ICV or IP astressin X IP CRF on plasma CORT. Cannulated mice (n = 6 per 
group) were pre-treated with astressin, either ICV (0 or 2 µg) or IP injection (35 µg/kg/5 ml), and 
after 15 min were IP injected with CRF (0 or 5 µg/kg/5 ml). The cannulas were removed (time = 
min 0) and the mouse returned to its home cage and colony room, and retrieved at min 20, 60 
and 120 for serial blood sampling. To test effects of ICV astressin, groups were icvVEH+ipVEH, 
icvVEH+ipCRF and icvAST+ipCRF. To test effects of IP astressin, groups were ipVEH+ipCRF 
and ipAST+ipCRF. 
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viii. Effect of ICV or IP astressin X ICV CRF on locomotor activity. Cannulated mice (n = 6 
per group) were pre-treated with astressin, either ICV infusion or IP injection, and after 15 min 
were ICV infused with CRF (1 µg). The cannulas were removed and the mouse placed in the 
activity monitoring apparatus for 50 min. At the end of this period they were blood sampled. To 
test effects of ICV astressin, groups were icvVEH+icvVEH, icvAST+icvVEH, icvVEH+icvCRF 
and icvAST+icvCRF. To test effects of IP astressin, groups were ipVEH+icvVEH, 
ipVEH+icvCRF and ipAST+icvCRF. 
2.10. RIA of ACTH and corticosterone and fluorescent EIA of CRF, in plasma 
Immunoreactive (ir) ACTH in mouse plasma was measured using a radioimmunoassay (RIA) kit 
for direct determination of human ACTH in EDTA plasma (DiaSorin, Stillwater, MN, USA). We 
had previously adapted and validated the kit for use with rat EDTA plasma without extraction 
(Pryce et al., 2003). The assay principle was competitive, equilibrium RIA, with an antiserum of 
rabbit anti-ACTH, 125I-ACTH as trace, and goat anti-rabbit serum as precipitating complex. For 
plasma samples from Expts (i), (ii) and (vii), EDTA-plasma pools were used to validate the kit for 
use with these samples, in terms of parallelism and accuracy. A single ACTH determination per 
sample was conducted using 25 µl per RIA tube. All samples per experiment were included in 
the same assay and intraassay precision was 8.1% (n = 6). For plasma samples from Expts (iii)-
(iv), validation of the RIA in terms of parallelism and accuracy could not be demonstrated using 
plasma pools derived from aliquots of these samples.  
In samples from Expts (i)-(iv) and (vi), ir CORT was estimated using an in house RIA described 
previously for rat plasma (Pryce et al., 2001), following validation (parallelism and accuracy) for 
mouse EDTA plasma. All samples per experiment were included in the same assay in duplicate. 
Intra-assay precision was 3.6% (n = 6) and inter-assay precision was 4.9% (n = 6).  
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Plasma ir CRF was estimated in mouse trunk-blood plasma samples from Expt (v). Plasma 
samples (100 µl) were run through C-18 SEP-columns and eluates were lyophilized over-night. 
The sample residues were reconstituted in assay buffer, centrifuged, and supernatants were 
assayed for ir CRF using a CRF fluorescent enzyme immunoassay (EIA) kit (FEK-019-06, 
Phoenix Pharmaceuticals Inc., Burlingame, CA, USA), validated in-house for mouse plasma. All 
samples were included in the same assay and intra-assay precision was 11.0% (n = 6). 
2.11. Statistics 
Statistical testing was conducted using SPSS (Version 16), with significance set at  ≤ 0.05. 
Data in Expts (i)-(iii) were analysed using General Linear Model repeated measures analysis of 
variance (ANOVA) with a within-subject factor of Time. Data in Expts (iv)-(vii) were analysed 
using linear mixed model ANOVA, with a between subject factor of Dose or Group and a within 
subject factor of Time. Following a significant main effect or interaction effect, post hoc testing 
was conducted using the Bonferroni test, to control for multiple comparisons. Data are plotted 
as means and standard deviations. 
3. Results 
3.1. Expt i. Effect of serial blood sampling (SBS) on plasma ACTH and CORT 
Plasma-ir ACTH and CORT titres in mice exposed to SBS are given in Figure 1A. For 
ACTH, there was a significant main effect of the repeated measure of Time (F(3, 21) = 40.64, p 
< 0.0001). Post hoc analysis demonstrated that ACTH titres were greater at min 20 than min 0 
(p < 0.004), 60 and 120 (p’s < 0.0001). For CORT, there was a significant main effect of the 
repeated measure of Time (F(3, 21) = 18.70, p < 0.0001). Post hoc analysis demonstrated that 
CORT titres were greater at min 20 than min 0 (p < 0.001) and 120 (p < 0.04), and greater at 
min 60 than min 0 and 120 (p’s < 0.001). 
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3.2. Expt ii. Effect of physical confinement and SBS on plasma ACTH and CORT 
Plasma-ir ACTH and CORT titres in mice exposed to physical confinement + SBS are 
given in Figure 1B. For ACTH, there was a significant main effect of the repeated measure of 
Time (F(3, 21) = 16.10, p < 0.0001). Post hoc analysis demonstrated that ACTH titres were 
greater at min 0 than min 60 (p < 0.01) and 120 (p < 0.002), and greater at min 20 than min 60 
and 120 (p’s < 0.03). For CORT, there was a significant main effect of the repeated measure of 
Time (F(3, 21) = 26.91, p < 0.0001). Post hoc analysis demonstrated that CORT titres were 
greater at min 20 than min 0 (p < 0.006), 60 (p < 0.004) and 120 (p < 0.0001), and greater at 
min 60 than 120 (p < 0.01). 
    FIGURE 1 ABOUT HERE 
3.3. Expt iii. Effect of ICV saline infusion and SBS on plasma ACTH and CORT 
 Plasma-ir ACTH and CORT titres in mice ICV-infused with saline followed by SBS are 
given in Figure 2A. For ACTH (F(2,10) = 1.17, p > 0.34) and CORT (F(2, 10) = 2.92, p > 0.10) 
there was no effect of sampling Time on plasma titres, in contrast to the findings of Expts i and 
ii. 
 A comparison of titres at the min-20 sampling point in Expts (i)-(iii) is provided in Figure 
2B. For ir ACTH, SBS and physical confinement + SBS induced similar mean titres, whereas 
the mean titre induced by ICV saline infusion was higher. Furthermore, this relatively high titre 
was maintained until min 120 (Figure 2A), rather than returning to basal titres by min 60 as 
occurred following SBS and physical confinement + SBS (Figure 1). This marked increase in ir 
ACTH following ICV saline was not reflected in the mean ir CORT response to ICV saline 
infusion at min 20: the latter was similar to the mean CORT titre induced by SBS and less than 
the mean CORT titre induced by physical confinement + SBS. 
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    FIGURE 2 ABOUT HERE 
3.4. Expt iv. Effect of ICV CRF infusion on plasma ACTH and CORT 
For plasma ir ACTH titres following ICV CRF infusion (Figure 3A), there was no 
significant effect of Dose (F(4, 40) = 2.51, p = 0.09) and a significant main effect of Time (F(2, 
40) = 4.92, p < 0.01). Post hoc analysis of Time demonstrated that ACTH titres were greater at 
min 20 than min 60 (p < 0.03) and 120 (p < 0.03). For plasma CORT titres (Figure 3B), there 
was a significant Dose x Time interaction (F(6, 40) = 4.49, p < 0.001) and significant main 
effects of Dose (F(4, 40) = 22.26, p < 0.0001) and Time (F(2, 40) = 12.63, p < 0.0001). Post hoc 
analysis of Dose demonstrated that 1 µg resulted in greater CORT titres than VEH, 0.001 µg 
and 0.01 µg (p’s < 0.0001), and 0.1 µg resulted in greater CORT titres than VEH and 0.001 µg 
(p’s < 0.0001). Post hoc analysis of Time demonstrated that CORT titres were greater at min 60 
than min 120 (p < 0.0001). 
It was systematically observed in this experiment that mice infused with 1 µg CRF were 
relatively inactive in their home cage during intervals between blood sampling and were also 
relatively behaviourally unresponsive during blood sampling. 
    FIGURE 3 ABOUT HERE 
3.5. Expt v. Effect of ICV CRF infusion on plasma CRF 
For plasma ir CRF (Figure 4), basal titres were 15-80 pg/ml. Subjects ICV infused with 
VEH exhibited approximately 100 pg/ml, and ICV CRF infusion resulted in a dose-related 
increase, with an approximate 10-fold increase versus VEH with 0.1 µg CRF and a 
proportionate, further 10-fold increase following 1 µg CRF. 
    FIGURE 4 ABOUT HERE 
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3.6. Expt vi. Effect of pretreatment with ICV or IP astressin on ICV CRF-induced increase 
in plasma CORT 
Plasma CORT titres in mice ICV infused with VEH or 0.1 µg CRF following pre-treatment 
with VEH or 2 µg ICV astressin, are given in Figure 5A. There was a significant Group x Time 
interaction (F(6, 34) = 11.16, p < 0.0001) and significant main effects of Group (F(3, 17) = 4.40, 
p < 0.02) and Time (F(2, 34) = 25.55, p < 0.0001). Post hoc analysis of Time demonstrated that 
CORT titres were greater at min 20 than min 60 (p < 0.005) and 120 (p < 0.0001), and greater 
at min 60 than min 120 (p < 0.002). A posteriori Group-Time analysis demonstrated that CORT 
titres were greater in icvVEH/icvCRF mice than in icvVEH/icvVEH mice at min 20 and 60, and 
icvAST/icvVEH mice at min 20; and were greater in icvAST/icvCRF mice than in icvAST/icvVEH 
mice at min 20 (Figure 5A). CORT titres were similar in the groups icvVEH/icvCRF and 
icvAST/icvCRF; therefore, there was no indication that ICV astressin inhibited the increase in 
plasma CORT induced by ICV CRF. 
In order to test whether peripherally administered astressin inhibited ICV CRF-induced 
increased plasma CORT, mice were pre-treated with VEH or 35 µg/kg astressin and then 
infused ICV with 0.1 µg CRF. Plasma CORT titres are given in Figure 5B. There was a 
significant Group x Time interaction (F(2, 24) = 9.88, p < 0.001) and significant main effects of 
Group (F(1, 24) = 82.48, p < 0.0001) and Time (F(2, 24) = 13.26, p < 0.0001). A posteriori 
Group-Time analysis demonstrated that CORT titers were reduced in ipAST/icvCRF mice 
relative to ipVEH/icvCRF mice at min 20 and 60 (Figure 5B). 
    FIGURE 5 ABOUT HERE 
3.7. Expt vii. Effect of pretreatment with ICV or IP astressin on IP CRF-induced increase 
in plasma CORT. 
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 This experiment was carried out in order to test whether IP CRF led to increased plasma 
CORT and whether ICV astressin or IP astressin inhibited the effect of IP CRF on plasma 
CORT: IP CRF-induced increased plasma CORT that could not be blocked by ICV astressin 
would provide supportive evidence that the observed ICV CRF-induced increased plasma 
CORT, that could not be blocked by ICV astressin, was mediated in the periphery. Plasma 
CORT titres in mice IP injected with CRF (0 or 5 µg/kg) following pre-treatment with ICV 
astressin (0 or 2 µg), are given in Figure 6A. There were significant main effects of Group (F(2, 
14) = 11.93, p < 0.001) and Time (F(2, 28) = 42.26, p < 0.0001). Post hoc analysis of Group 
demonstrated that plasma CORT was significantly increased in icvVEH/ipCRF mice versus 
icvVEH/icvVEH (p < 0.01) mice, and in icvAST/ipCRF mice versus icvVEH/icvVEH mice (p < 
0.05), with no significant difference between icvAST/ipCRF and icvVEH/ipCRF mice (p > 0.10). 
Post hoc analysis of Time demonstrated that plasma CORT was significantly increased at min 
20 versus 120 (p < 0.0001) and min 60 versus 120 (p < 0.0001).  
Plasma CORT titres in mice IP injected with CRF following pre-treatment with IP 
astressin (35 µg/kg) are given in Figure 6B. There were significant main effects of Group (F(1, 
8) = 17.35, p < 0.003) and Time (F(2, 16) = 7.57, p < 0.005). Plasma CORT titres were 
significantly decreased in ipAST/ipCRF mice versus ipVEH/ipCRF mice. Post hoc analysis of 
Time demonstrated that plasma CORT was significantly increased at min 60 versus 120 (p < 
0.004). Because this experiment did not involve ICV infusion, plasma ACTH titres were also 
measured (Figure 6B). There were significant main effects of Group (F(1, 24) = 10.29, p < 
0.004) and Time (F(2, 24) = 11.94, p < 0.0001). Plasma ACTH titres were significantly 
decreased in ipAST/ipCRF mice versus ipVEH/ipCRF mice. Post hoc analysis of Time 
demonstrated that plasma ACTH was significantly increased at min 20 versus 60 (p < 0.04) and 
120 (p < 0.0001). 
18 
 
    FIGURE 6 ABOUT HERE 
3.8. Expt viii. Effect of pretreatment with ICV or IP astressin on ICV CRF-induced 
decrease in locomotor activity 
Given the absence of an effect of ICV astressin on the ICV CRF readout of plasma 
CORT, we investigated for a central effect of astressin in terms of whether ICV astressin could 
inhibit the ICV CRF-induced decreased locomotor activity observed in Expt. iv. Locomotor 
activity of mice infused with ICV VEH or astressin (2 µg) followed by ICV VEH or CRF (1 µg) are 
given in Figure 7A. There were significant main effects of Group (F(3, 17) = 5.30, p < 0.009) and 
Time (F(9, 153) = 16.40, p < 0.0001). Post hoc analysis of Time demonstrated that distance 
moved during min 1-5 (overall mean  SD = 1194  325 arbitrary units, n = 21) was greater 
than in each other 5-min block (e.g. min 6-10, 609  403 arbitrary units) (p’s < 0.004), and 
that there were no further time-block differences. Post hoc analysis of Group demonstrated 
that distance moved was greater in AST/CRF mice than VEH/CRF mice (p < 0.05) and in 
AST/VEH mice than VEH/CRF mice (p < 0.01). In blood samples taken immediately after 
removal of the mice from the activity chambers, there was a significant Group effect on plasma 
CORT titres (F(3, 17) = 32.98, p < 0.0001; Figure 7B) with titres greater in VEH/CRF than 
VEH/VEH and AST/VEH mice (p’s < 0.0001), and greater in AST/CRF than VEH/VEH and 
AST/VEH mice (p’s < 0.0001), and no significant difference between AST/CRF and VEH/CRF 
mice. 
We also tested whether IP astressin could inhibit ICV CRF-induced decreased locomotor 
activity: a lack of effect would provide supportive evidence that this effect of astressin was 
centrally-mediated. Distances moved in mice pre-treated with IP astressin (0 or 35 µg/kg) 
followed by ICV CRF (0 or 1 µg) are given in Fig 7C. There were significant main effects of 
Group (F(2, 9) = 16.44, p < 0.001) and Time (F(9, 81) = 12.66, p < 0.0001). Post hoc analysis of 
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Group demonstrated that distance moved was significantly reduced in ipVEH/icvCRF versus 
ipVEH/icvVEH (p < 0.04) and in ipAST/icvCRF versus ipVEH/icvVEH (p < 0.01), with no 
significant difference between ipAST/icvCRF and ipVEH/icvCRF (p = 1) (Figure 7C). 
    FIGURE 7 ABOUT HERE 
4. Discussion 
The current experiments carried out with C57BL/6 mice demonstrate that: (1) ICV saline 
infusion led to a marked, sustained increase in immunoreactive plasma ACTH and a mild 
increase in plasma CORT, relative to the respective increases induced by physical confinement 
and serial blood sampling. (2) ICV CRF infusion at 0.001-1 µg induced no further increase in 
plasma ACTH versus vehicle, and induced dose-dependent increases in plasma CORT. ICV 
CRF at 1 µg also reduced home cage locomotor activity. (3) ICV CRF induced dose-dependent 
increases in plasma CRF. (4) ICV astressin failed to block ICV CRF-induced increased plasma 
CORT, whereas IP astressin did do so. (5) ICV astressin failed to block IP CRF-induced 
increased plasma CORT, whereas IP astressin did do so, as well as blocking IP CRF-induced 
increased plasma ACTH. (6) ICV CRF-induced locomotor inactivity was blocked by ICV 
astressin, but not by IP astressin.  
In demonstrating the dose-dependent effect of ICV CRF on plasma CORT levels the present 
study provides similar findings to those reported for the rhesus macaque, in which 1 and 10 
µg/kg ICV CRF yielded increased plasma cortisol levels (Rock et al. 1984). In the rat, a study of 
intra-venous CRF demonstrated that 0.1-10 µg yielded dose-dependent increases in plasma 
ACTH but dose-independent increases in plasma CORT (Rivier et al. 1982). In a pilot study that 
we carried out in Lister-hooded rat to establish the methodology for this mouse study, ICV CRF 
at 0.1, 1 and 10 µg yielded dose-dependent increases in plasma ACTH and CORT (unpublished 
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data). In mouse, a previous study in C57BL/6N mice with 0.1-1 µg/kg ICV CRF demonstrated 
dose-independent increases in plasma CORT (Warnock et al. 2009). 
The experiments (i, ii, iii) with serial blood sampling (SBS), confinement in a novel tube and 
SBS, and ICV saline infusion, were carried out to establish the magnitude and time course of 
the plasma ACTH-CORT responses to moderate stressors and to biologically validate the 
immunoassays for ACTH and CORT in this mouse strain. For plasma ACTH, levels were 
highest within the first 20 min following physical confinement/SBS onset followed by a 
monotonic decline and a return to basal levels. For plasma CORT, the maximum mean level 
was at min 20-60 post-stressor followed by a monotonic decline. Therefore, stress responses 
were detectable for both plasma ACTH and CORT and, as expected, the ACTH peak preceded 
the CORT peak. In contrast, when ICV saline was the stressor, there was a relatively marked 
increase in plasma ACTH immunoreactivity at min 20 and this was maintained until min 120. 
Plasma CORT exhibited only a mild increase, strongly suggesting that ICV saline infusion was a 
mild stressor. One possible explanation for this marked increase in plasma ACTH 
immunoreactivity as measured in the RIA is that the solution injected ICV (3 µl in total) led to a 
mechanical displacement of cerebrospinal fluid/injected fluid into the pituitary, which in turn 
induced washing out of pituitary peptides into the blood, including peptides that cross-react in 
the ACTH RIA. Candidates would include proopiomelanocortin (POMC), α-melanocyte 
stimulating hormone (MSH, ACTH1-13) and corticotropin-like intermediary lobe peptide (CLIP, 
ACTH18-39). The cross-reactivity of these non-ACTH peptides with the RIA kit antibody used is 
unknown, but in other ACTH assays, even in specific two-site immunoradiometric assays, it has 
been demonstrated that CLIP cross-reactivity can be marked and that MSH and POMC 
impedance of ACTH binding also can occur (e.g. (Guiban et al. 2001)). These experiments 
demonstrate that plasma ir-ACTH determinations would not be a valid marker of ICV CRF 
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effects. There was no evidence to indicate that plasma CORT would not provide a valid marker; 
in fact, the ICV infusion procedure led to only a mild increase in plasma CORT. 
In the ICV CRF expt (iv), even at 1 µg CRF there was no consistent increase in ir-ACTH relative 
to saline, suggesting a floor-effect in the method, as discussed above. For plasma CORT, there 
was a dose-dependent increase in response to ICV CRF, with doses of 0.1 and 1 µg yielding a 
significant increase. The increase was maximal at min 60 and the longevity of the increase was 
also dose-dependent. At 0.1 µg the absolute levels and the time profile of the plasma CORT 
response were similar to those observed following the SBS and physical confinement stressors. 
These dose-dependent findings strongly suggest that plasma CORT provides an accurate 
marker for ICV CRF infusion in mouse, in agreement with previous studies e.g. (Warnock et al. 
2009). Because of the low solubility of astressin in artificial CSF (see below), neither CRF 
nor astressin was administered in aCSF (CRF was infused in saline and astressin in 
water). ICV CRF was administered in saline in a number of previous ICV CRF rodent studies 
e.g. (Bittencourt and Sawchenko 2000; Warnock et al. 2009). To check that the current findings 
with ICV CRF were not specific to saline vehicle, we also repeated the ICV CRF experiment 
using aCSF as vehicle and obtained the same findings (unpublished data). What requires 
clarification is the pathway via which ICV CRF leads to dose-dependent increases in plasma 
CORT. 
To attempt to gain insight into this pathway was the rationale for measuring ir-CRF levels in 
whole-blood plasma at 10 min following ICV CRF infusion (expt v). There was a dose-
dependent increase in plasma CRF levels at 0.1 and 1 µg ICV CRF relative to basal and ICV 
VEH infusion levels, which were approximately 100 pg/ml. Assuming that the majority of this 
increase was accounted for by exogenous CRF, these data are consistent with the passage of 
exogenous CRF from the ventricles into the pituitary and the peripheral circulation. At the 
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pituitary, the exogenous CRF would stimulate ACTH release. Given the lack of robust evidence 
for an ICV CRF-induced plasma ACTH increase, it is possible that ICV CRF entered the 
periphery and acted directly at the adrenal gland to stimulate CORT secretion. However, this is 
unlikely given the evidence for a complete lack of effect of IV CRF on CORT levels in 
hypophysectomized rats (Rivier et al. 1982). Further supportive evidence for the interpretation 
that the ICV CRF-induced increase in plasma CORT was indeed mediated in the periphery and 
by increased ACTH was provided by the ICV and IP astressin experiments, as discussed below. 
Astressin is a potent antagonist at CRF R1 (Ki = 12 nM) and CRF R2 (Ki = 1.5 nM). It inhibits 
ACTH secretion in vitro and, following IV infusion, in vivo (Steckler and Dautzenberg 2006). 
Relative to other CRF R1/R2 antagonists, e.g. αhelCRF9-41, astressin has low solubility in 
artificial CSF (Brauns et al. 2001). It has been proposed that low solubility in CSF could reduce 
the antagonistic efficacy of ICV astressin in in vivo readouts: For example, in BALB/c mice, 0.3 
µg ICV astressin did not reduce anxiety on the elevated plus maze (Brauns et al. 2001). In rat, 5 
µg ICV astressin was required to antagonize the anxiogenic effect of 0.5 µg ICV CRF on the 
elevated plus maze (Spina et al. 2000), and a dose of 10 µg ICV astressin was required to 
partially inhibit the increase in plasma ACTH induced by 4 µg/kg IV CRF (Rivier et al. 1996); an 
IV dose of 300 µg/kg astressin inhibited the increase in plasma ACTH induced by 4 µg/kg IV 
CRF (Rivier et al. 1996). 
In the present study (expt vi), 2 µg ICV astressin was without effect on the increase in plasma 
CORT levels induced by 0.1 µg ICV CRF. Astressin administered IP did antagonize the ICV-
CRF induced plasma CORT increase. Together, these findings strongly suggest that ICV CRF 
exerted its effect on plasma CORT in the periphery and, in contrast to CRF, that astressin, at 
the dose used, did not pass through the ventricles into the circulation and pituitary. Similarly, 
when CRF was administered IP (expt vii) the observed increase in plasma CORT was not 
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antagonized by ICV astressin but was antagonized by IP astressin. In the IP astressin/IP CRF 
experiment, both plasma ACTH and CORT were increased by CRF and antagonized by 
astressin, suggesting that the similar increases observed in plasma CORT following ICV CRF 
were also mediated by increased plasma ACTH. Therefore, several lines of evidence of this 
mouse study are consistent with ICV CRF exerting its effects on plasma CORT levels at the 
level of the pituitary and, therefore, that plasma CORT does not constitute either a suitable 
marker of ICV CRF activity in the CNS or the antagonism of this central activity by CRF R1/2 
antagonism. The rationale for this study was to provide evidence of pathways via which 
exogenous CRF stimulates CORT and impacts on behaviour, thereby identifying 
readouts for the study of CRF-R antagonists on CRF-induced effects. In the course of the 
study it was demonstrated that the procedures used, e.g. ICV infusion, per se caused 
consistent increases in plasma CORT and, although not studied here, it would be of 
interest to investigate whether these responses, which quite possibly are mediated by 
increased endogenous CRF/urocortin, are also blocked by astressin, either given IP or 
ICV. 
In contrast to a lack of effect on the increase in plasma CORT levels induced by ICV CRF, 2 µg 
ICV astressin did antagonize the inhibitory effect of 1 µg ICV CRF on locomotion (expt vii). This 
effect was independent of plasma CORT: ICV AST/ICV CRF mice exhibited increased plasma 
CORT levels but normal levels of locomotion. That this effect of ICV astressin was indeed 
mediated directly centrally was indicated by the lack of effect of IP astressin on ICV CRF 
induced hypo-locomotion (expt viii). The locomotion test was performed as a simple readout for 
ICV CRF behavioural effects and the effects of CRF R antagonism thereon, based on the 
consistent observation of hypo-activity of mice in the home cage following 1 µg ICV CRF. It is 
well-established in rat that ICV CRF leads to increased locomotor activity in a familiar cage and 
decreased activity in a novel open field (Koob et al. 1993; Sutton et al. 1982). In CD-1 albino 
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mice, 0.1 µg ICV CRF led to decreased activity in a novel open field and increased time spent in 
the centre of the open field related to a delay in leaving the centre after being placed there at 
the onset of the test (Swiergiel et al. 2008). In our study the test apparatus was not novel to the 
mice: we performed two habituation sessions in an attempt to increase the similarity of the 
response to the hypo-locomotion in the home cage observed in response to 1 µg ICV CRF. 
Given that ICV CRF penetrates throughout the rodent brain into a number of regions expressing 
CRF R1 and/or R2, as demonstrated using FOS expression in rat (Bittencourt and Sawchenko 
2000) and local cerebral glucose utilization in mouse (Warnock et al. 2009), for example, then it 
is parsimonious to avoid speculation on the emotional-motivational state induced by 1 µg ICV 
CRF and underlying the consistent reduction in locomotor activity observed. Nonetheless, this 
consistent reduction in locomotor activity provides a basic readout for ICV CRF central activity 
as well as for the centrally-mediated antagonism of this behavioural readout by CRF R 
antagonism. It is unclear from the current data whether this behavioural effect of ICV CRF is 
mediated and antagonized via CRF R1 and/or R2. 
The present findings can be compared to those reported for mice manipulated genetically to 
over-express CRF in the brain. Non-conditional transgenic over-expression of the CRF gene 
would, in broad terms, be expected to result in a chronic form of what ICV CRF appeared to 
induce acutely in the current experiments, namely increased central and peripheral CRF levels. 
Such mice do indeed exhibit increased basal plasma ACTH and CORT levels relative to 
wildtype mice, and reduced locomotor activity, at least in a novel environment (Stenzel-Poore et 
al. 1992; Stenzel-Poore et al. 1994). Conditional transgenic mice that over-express CRF in the 
forebrain specifically did not exhibit altered basal plasma ACTH and CORT levels relative to 
wildtype. This was the case despite a strong decrease in endogenous CRF expression in the 
hypothalamic PVN, from which reduced basal ACTH and CORT levels would be expected (Lu et 
al. 2008). Based on the current findings it would be worthwhile to measure plasma CRF levels in 
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such conditional CRF over-expressing mice, given that any increased transfer from the brain to 
the periphery could act on pituitary corticotrophs directly. 
Therefore, this study has provided evidence that, in BL/6 mice, ICV CRF induces a dose-
dependent increase in plasma CORT via a peripheral pathway and a reduction in locomotion via 
a central pathway. It has provided evidence for a double dissociation of the ability of astressin to 
antagonize these effects relative to its route of administration: only IP astressin antagonized the 
ICV CRF induced increase in plasma CORT and only ICV astressin antagonized the ICV CRF 
induced decrease in locomotion. Given that the lack of effect of ICV astressin on plasma 
CORT was demonstrated using a single dose only, then it can of course not be 
concluded that ICV astressin at higher doses would not reduce plasma CORT responses 
to ICV CRF. Nonetheless, the crucial point to note here is that the dose of ICV astressin 
that did not antagonize the effect of ICV CRF on plasma CORT did antagonize the effect 
of ICV CRF on motor activity. As such, the preparation described here could be used to 
provide initial indications on the central and peripheral activity of CRF-R antagonists, including 
pharmacokinetics following peripheral administration. 
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Figure legends 
Figure 1. Plasma titres of ACTH (filled squares) and CORT (open circles) in naive C57BL/6 
mice, (A) across serial tail-vein blood sampling at min 0, 20, 60 and 120, (B) following 5-min 
confinement in a novel environment (transparent plastic tube; indicated by grey bar) + serial 
blood sampling at min 20, 60 and 120. In (B), values at time point 0 min were measured in blood 
samples collected from a separate group of naive mice immediately following removal from the 
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home cage. In (A) and (B), values are mean+/-SD for n = 8. Data points denoted by different 
letters are significantly different in post hoc pairwise comparisons, upper case for ACTH and 
lower case for CORT. 
Figure 2. (A) Plasma titres of ACTH (filled squares) and CORT (open circles) in cannulated mice 
infused ICV with saline (indicated by grey bar) and serially blood sampled. Values at time point 
0 min were measured in blood samples collected from a separate group of naive mice 
immediately following removal from the home cage. Values are mean+/-SD for n = 6. There was 
no significant effect of sample time following ICV saline for ACTH or CORT. (B) Visual 
comparison of plasma ACTH and CORT titres following different stressors: basal titres; at min 
20 following blood sampling at min 0; at min 20 following physical confinement at min 1-5; at 
min 20 following ICV saline infusion at min 1-5. 
Figure 3. In cannulated C57BL/6 mice, effect of various doses of bilateral ICV CRF on plasma 
titres of (A) ACTH and (B) CORT. Serial tail-vein blood samples were obtained at min 20, 60 
and 120 post-CRF infusion from mice kept in their home cage/room. Values are mean+SD for n 
= 5-6 per group. Doses denoted by different letters yielded significantly different plasma CORT 
titres in post hoc pairwise comparisons. 
Figure 4. In cannulated C57BL/6 mice, effects of ICV or IP saline (VEH) or ICV CRF on plasma 
titres of CRF. Values are individual data points for mice from which trunk blood was collected 
either immediately after removal from the home cage (Basal, n = 3), 10 min after ICV infusion of 
VEH (n = 4), 0.1 µg CRF (n = 3) or 1 µg CRF (n = 3), or IP VEH injection (n = 3). 
Figure 5. In cannulated C57BL/6 mice, effects of prior treatment with (A) bilateral ICV astressin 
(2 µg in 4 µl) or (B) IP astressin (35 µg/kg), on bilateral ICV CRF (0.1 µg in 3 µl) induction of 
increased plasma CORT titres. Serial tail-vein blood samples were obtained at min 20, 60 and 
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120 post-CRF infusion. Values are mean+SD for n = 5-6 mice per group. * p < 0.05, ** p < 0.01 
for post hoc pairwise comparisons of data points.  
Figure 6. (A) In cannulated C57BL/6 mice, effects of prior treatment with bilateral ICV astressin 
(2 µg in 4 µl) on IP CRF (5 µg/kg) induction of increased plasma CORT titres. (B) In non-
cannulated C57BL/6 mice, effects of prior treatment with IP astressin (35 µg/kg) on IP CRF (5 
µg/kg) induction of increased plasma CORT and ACTH titres. Serial tail-vein blood samples 
were obtained at min 20, 60 and 120 post-CRF infusion. Values are mean+SD for n = 5-6 mice 
per group. Treatment groups denoted by different letters yielded significantly different plasma 
CORT or ACTH titres. 
Figure 7. (A) In cannulated C57BL/6 mice, effects of prior treatment with bilateral ICV astressin 
(2 µg in 4 µl) on ICV CRF (1 µg in 3 µl) induction of locomotor hypoactivity. The graph depicts 
the treatment group overall mean+SD per 50 min test for n = 5-6 animals per group. Treatment 
groups depicted by different letters exhibited significantly different locomotor activity. (B) For the 
same mice, effects of ICV astressin and ICV CRF on plasma CORT titres (mean+SD) in blood 
samples collected immediately after the 50-min activity test. Treatment groups depicted by 
different letters exhibited significantly different plasma CORT titres. (C) In cannulated C57BL/6 
mice, effects of prior treatment with IP astressin (35 µg/kg) on ICV CRF (1 µg in 3 µl) induction 
of locomotor hypoactivity. Values are mean+SD for n = 4 mice per group. Treatment groups 
depicted by different letters exhibited significantly different locomotor activity. 
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